Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06920901 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Immunogenicity of APG777 in Adults With Asthma
A Phase 1 study of Asthma, sponsored by Apogee Therapeutics.
- Active
- Registry status
- Phase 1
- Development phase
- 31
- Enrollment target
- 11
- Study locations
NCT06920901 is a Phase 1 study of Asthma that is active but no longer recruiting, run by Apogee Therapeutics. The registered enrollment target is 31 participants, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (98% lower). The trial reports 11 study locations across 7 states.
The verdict
NCT06920901, a Phase 1 study of Asthma, is active but no longer recruiting, sponsored by Apogee Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 31 participants
- Enrollment target
- 11
- Study locations
Study Summary
This is a multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, PK, and immunogenicity of APG777 in adult participants with mild-to-moderate asthma. The duration of the study will be approximately 52 weeks (364 days) for each participant and will consist of a Screening Period, Treatment Period, and Follow-up Period.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG APG777
Study Locations (11)
California
- Investigational Site - La Jolla
- Investigational Site - Long Beach
- Investigational Site - San Jose
- Investigational Site - Torrance
Pennsylvania
- Investigational Site - Philadelphia
- Investigational Site - Pittsburgh
Illinois
- Investigational Site - Normal
Missouri
- Investigational Site - Kansas City
Oklahoma
- Investigational Site - Edmond
West Yorkshire
- Investigational Site - Bradford
Other
- Investigational Site - Manchester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2025-03-27 |
| Est. Completion | 2027-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06920901
The ClinicalTrials.gov registry entry for NCT06920901 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (98% lower). The listed sponsor is Apogee Therapeutics, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Asthma appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06920901 reports 11 study locations spanning 7 distinct geographic areas - top geographies include California, Pennsylvania, Illinois.
Frequently Asked Questions
What is clinical trial NCT06920901 about?
NCT06920901 is a clinical study titled "A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Immunogenicity of APG777 in Adults With Asthma". This is a multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, PK, and immunogenicity of APG777 in adult participants with mild-to-moderate asthma. The duration of the study will be approximately 52 weeks (364 days) for each participant and will cons...
What is the current status of trial NCT06920901?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 31 participants. The study started on 2025-03-27. Estimated completion is 2027-03.
What conditions does trial NCT06920901 study?
This clinical trial studies the following conditions: Asthma.
What interventions are being tested in trial NCT06920901?
The interventions under investigation include: Placebo (DRUG), APG777 (DRUG).
Who is sponsoring clinical trial NCT06920901?
This trial is sponsored by Apogee Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06920901 being conducted?
This trial has 11 study locations across California, Illinois, Missouri, Oklahoma, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Asthma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Hyperpolarized 129Xe MR Imaging of Lung Function in Healthy Volunteers and Subjects With Pulmonary Disease
RECRUITING · Phase 1
-
A Study to Investigate How Budesonide and Formoterol Move Through the Body (Pharmacokinetics) When Delivered With Different Devices in Participants Aged 4 to Less Than 12 Years Old With Asthma
RECRUITING · Phase 1
-
Pilot Study to Identify the Mediators and Inflammatory Cell Surface Receptors Involved in Allergic Airway Inflammation
RECRUITING · Phase 1
-
A Phase 1, Randomized, Double-blind, Placebo-controlled Study Evaluating AMG 691 in Healthy Participants and Participants With Mild-to-Moderate Asthma
RECRUITING · Phase 1
-
A Study to Investigate GB-0895 in Adults With Mild to Moderate Asthma or COPD
ACTIVE NOT RECRUITING · Phase 1
-
Symptom-driven ICS/LABA Therapy for Patients With Asthma Non-adherent to Daily Maintenance Inhalers
ACTIVE NOT RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.